Daily Archives: May 2, 2023


Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

May 2nd, 2023 Blood cancer, Cancer, Lymphoma

May 2023: For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score o.... Read More

Omidubicel - 2 May (1)

Omidubicel is approved by USFDA to reduce time to neutrophil recovery and infection in patients with hematologic malignancies

May 2nd, 2023 Blood cancer, Cancer

May 2023: Omidubicel-onlv (Omisirge, Gamida Cell Ltd.) was approved by the Food and Drug Administration for use in adult and paediatric patients (12 years of age and older) with hematologic malignancies who are scheduled to receive an umbilical.... Read More

Padcev for urothelial cancer treatment

Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma

May 2nd, 2023 Cancer, Urethral cancer

May 2023: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck) have been given accelerated approval by the Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelia.... Read More